March 8, 2024 — Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, today announced that it has launched its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States. This launch expands upon the company’s prior ENROUTETranscarotid Stent System, offering additional configurations to better tailor the Transcarotid Artery Revascularization (TCAR) procedure to patient anatomy. TCAR is a minimally invasive, surgical procedure designed to provide best-in-class stroke protection while minimizing adverse events.
“As pioneers in stroke prevention, our product development efforts are focused on extending our lead in the minimally invasive treatment of carotid artery disease,” said Chas McKhann, Chief Executive Officer of Silk Road Medical. “New tapered configurations for our ENROUTE Transcarotid Stent System build upon the robust portfolio of Silk Road’s carotid solutions. We are pleased to bring this portfolio expansion to market as part of our commitment to offering a diverse toolkit for physicians, allowing them to address individual patient anatomy.”
The ENROUTE Transcarotid Stent System is the only commercially available transcarotid stent system indicated for patients at high risk and standard risk for adverse events from carotid endarterectomy (CEA). The ENROUTE Transcarotid Stent System features an optimized cell design balancing lesion coverage and anatomical conformability for long-term plaque stabilization. The stent system was purpose-built for TCAR with a short delivery system for ergonomic and precise stent delivery.
“The new tapered stent is a welcome addition to my TCAR toolkit, further differentiating the Company’s core product offering,” said Joseph V. Lombardi, MD, MBA, FACS, Professor and Chief of Vascular Surgery, Cooper University Health Care. “The ENROUTE stent has always provided comprehensive lesion coverage and durable procedural outcomes, but I now have more options to customize treatment to each patient's anatomy.”
For more information: www.silkroadmed.com
Related content:
TCAR Achieves Favorable Outcomes Versus Carotid Endarterectomy in CAD Patients
Silk Road Medical Announces FDA 510(k) Clearance of the Enroute Transcarotid Neuroprotection System
October 02, 2024 
